Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Erytech Conducts Phase I Pancreatic Cancer Clinical Trial

By Drug Discovery Trends Editor | June 28, 2011

Erytech Pharma has completed enrollment of patients in a Phase I clinical trial with its product for pancreatic cancer, Graspa. 

This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by Erytech.  The first results in this study demonstrated that Graspa was active, with a safety profile that was satisfactory for patients in last-line therapy.  Bases on this success, Erytech is expecting to forge ahead with the clinical development of Graspa for the treatment of pancreatic cancer in responder patients.
 
“Graspa showed good safety and tolerability in these particularly fragile patients, whereas other clinical studies have shown significant toxicity with forms of asparaginase. We had obtained the same results in leukemia; it is the first time in a solid tumor,” Yann Godfrin, MD, Erytech’s co-founder, vice president and chief scientific officer.

Published academic studies and Erytech’s own research on mice and on patient samples have shown that a subgroup of tumors is sensitive to the action of L-asparaginase.  In order to select responders, Erytech is working with private-sector and academic partners with a view to fine-tuning a predictive test for the efficacy of encapsulated asparaginase. 

Graspa has been granted orphan drug designation by the European Medicines Agency for the treatment of pancreatic cancer.  It has also received this status in Europe and in the USA for the treatment of acute lymphoblastic leukemia.  Erytech use of encapsulation technology opens up new cancer treatment possibilities, in which enhanced efficacy and reduced toxicity are key elements in an improved prognosis and quality of life for patients.
 
 Release Date: June 27 2011
Source: Erytech Pharma  


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE